TRIB

Trinity Biotech PLC

TMT


Presented:10/29/2013
Price:$24.44
Cap:$0.53B
Current Price:$1.68
Cap:$0.02B

Presented

Date10/29/2013
Price$24.44
Market Cap$0.53B
Ent Value$0.50B
P/E Ratio25.66x
Book Value$8.50
Div Yield1.2%
Shares O/S21.59M
Ave Daily Vol90,000
Short Int0.86%

Current

Price$1.68
Market Cap$0.02B
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. It offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as bacterial and viral diseases, and autoimmune disorders; products for the in-vitro diagnostic testing for haemoglobin A1c (HbA1c) used in the monitoring and diagnosis of diabetes; Hb variants for the detection of Hemoglobinapothies; and reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for detecting liver and kidney diseases, and haemolytic anaemia. The company also provides UniGold HIV, a POC diagnostic test, which is carried out in the presence of the patient to diagnose the presence of HIV antibodies in the patient. In addition, it sells raw materials to the life sciences industry and research institutes. Its customers include hospitals, clinical and reference laboratories, public health facilities, and other outreach facilities. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Highlights

The presenter is long shares of Trinity Biotech (TRIB), a profitable medical diagnostics company headquartered in Ireland, and sees substantial upside potential for shareholders on the back of growth in point-of-care testing and the potential future success of Fiomi (a 2012 acquisition) and their development of a Troponin I (TnI) assay (to detect heart-attacks) and a BNP test (for heart disease/ failure).

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.